Review proposal consultation | Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | Guidance

NICE is considering whether new evidence has emerged that would affect the recommendation of TA762.

This page was last updated: 08 April 2024